All In Biotech

Drug Trial Radar · NCT03363893

Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies

A Modular, Multipart, Multiarm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of CT7001 Alone and in Combination With Anti-cancer Treatments in Patients With Advanced Malignancies

Last checked: Nov 19, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 124 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

124

Actual

Start

Nov 14, 2017

Primary completion

Dec 15, 2022

Study completion Dec 15, 2022

Sponsor

Lead sponsor
Carrick Therapeutics LimitedIndustry
Sponsor type
Industry
First posted
Dec 6, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a modular, Phase I/II, multicentre study to investigate CT7001 monotherapy in advanced solid malignancies and to further investigate CT7001 as monotherapy or in combination with standard therapy in specific participant groups with Triple Negative Breast Cancer (TNBC), Castrate Resistant Prostate Cancer (CRPC) and in combination with fulvestrant for patients with hormone receptor-positive (HR+ve) / human epidermal growth factor-2 negative (HER2-ve) breast cancer.

Conditions

  • Advanced Solid Malignancies

Interventions

  • CT7001Drug

    Cyclin-dependent kinase 7 (CDK7) inhibitor given orally once daily until disease progression

  • FulvestrantDrug

    Administered as 2 x 250mg intramuscular (IM) gluteal injections on Day 1, Day 15, Day 28 and every 28 days thereafter.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment-Emergent Adverse Events and Laboratory Abnormalities (Safety and Tolerability)Time frame: Screening to end of study (28-35 calendar days after end of treatment). End of treatment at disease progression, unacceptable toxicity or withdrawal of consent. Average time on study 142.6 days (range 9 - 1135 days)

Locations

23 sites in 2 countries. Site status is shown where the registry gives one.

  • Research Site 54

    Tucson, Arizona

  • Research Site 31

    Beverly Hills, California

  • Research Site 37

    Tampa, Florida

  • Research Site 38

    Chicago, Illinois

  • Research Site 34

    Boston, Massachusetts

  • Research Site 47

    Cincinnati, Ohio

  • Research Site 39

    Columbus, Ohio

  • Research Site 36

    Portland, Oregon

  • Research Site 44

    Austin, Texas

  • Research Site 46

    Dallas, Texas

  • Research Site 48

    Salt Lake City, Utah

  • Research Site 33

    Salem, Virginia

  • Research site 11

    Brighton, United Kingdom

  • Research site 5

    Cambridge, United Kingdom

  • Research Site 7

    Glasgow, United Kingdom

  • Research Site 10

    Liverpool, United Kingdom

  • Research Site 9

    London, United Kingdom

  • Research Site 8

    London, United Kingdom

  • Research Site 3

    London, United Kingdom

  • Research Site 1

    Manchester, United Kingdom

  • Research Site 4

    Manchester, United Kingdom

  • Research Site 2

    Oxford, United Kingdom

  • Research Site 6

    Southampton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.